Meet the Mandates 2026

PEDIATRIC ABUSIVE HEAD TRAUMA

Video available here

Evaluation: https://www.surveymonkey.com/r/PAHT2026

Accreditation:
The Kentucky Medical Association is accredited by the ACCME to provide continuing medical education for physicians.

Designation:  The Kentucky Medical Association designates this enduring material activity for 1.0 AMA PRA Category 1 credit.(TM) Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation Used: Participants will view and listen to a recorded lecture while simultaneously viewing slides.

Hardware/Software Requirements: High speed internet connection

Commercial Support: There is no commercial support associated with this activity.

Estimated Time to Complete: This module will take approximately 1.0 hour each to complete.

Statement of Need:

Kentucky continues to experience one of the nation’s highest rates of child maltreatment. In federal fiscal year 2024, 14,505 Kentucky children were identified as victims of abuse or neglect—a rate of 14.1 per 1,000 children, nearly twice the national rate of 7.2 per 1,000. Although the number of identified victims declined 13% between 2020 and 2024, Kentucky still ranked fifth highest nationally, and young children remain particularly vulnerable.

https://acf.gov/sites/default/files/documents/cb/cm2024.pdf?utm_source=chatgpt.com

Objectives:

  1. Define and describe the injuries involved in Pediatric Abusive Head Trauma.
  2. Recognize common early warning signs of physical abuse.
  3. Be able to recognize the indications for a complete occult trauma evaluation.
  4. Be able to document clearly and in detail when physical abuse is suspected.
  5. Define and comprehend the mandatory reporting laws in Kentucky as it pertains to medical providers.
  6. Cite 2 ways providers can help prevent pediatric abusive head trauma and child physical abuse in their interactions with children and their caregivers.

Disclosure: All planners and speakers associated with any of the activities listed below disclose that they have no relevant relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Meeting Planner: Miranda Mosley, Rachel Crouch

Provider Contact Information: Miranda Mosley, Kentucky Medical Association

Copyright: There is no copyright associated with this activity

Release Date: August 2026

Termination Date: December 2026

HOUSE BILL ONE

Access for each session can be found with each session’s title and speaker information.

Upon completion of entirety of activity, participants can access the evaluation for the full activity here: https://www.surveymonkey.com/r/MTMHB126

Commercial Support: There is no commercial support associated with this activity.

Accreditation and Designation:
The Kentucky Medical Association is accredited by the ACCME to provide continuing medical education for physicians.

The Kentucky Medical Association designates this enduring material for 4.5 AMA PRA Category 1 Credits.

Estimated Time to Complete: Each session will take approximately 1.0 hour to complete. 

Method of Participation Used: Participants will view and listen to a recorded lecture while simultaneously viewing slides.

Hardware/Software Requirements: High speed internet connection

Meeting Planner: Miranda Mosley, Rachel Crouch

Provider Contact Information: Miranda Mosley, Kentucky Medical Association

Copyright: There is no copyright associated with this activity

Release Date: September 2026

Termination Date: December 2026

For course titles,  speaker disclosure information, and session objectives, please see below.

Certificates will be e-mailed at the end of each month.

Challenges in the Treatment of Methamphetamine Addiction

Terry Rook, Jr. MCJ, LCDC III, LCADC, CCS

Disclosure: All planners and speakers associated with this session disclose that they have no relevant relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Watch session here: https://youtu.be/gbtt7U_rg6g

  • Improve ability to identify unique aspects/risks of methamphetamine use disorder
  • Improve my ability to more effectively treat methamphetamine use disorder in a variety of treatment environments or refer to specialist for treatment.
  • Include screening for patients in my patient encounters
  • Be able to more effectively educate clients/families about methamphetamine use disorder.

Medicinal Uses of Cannabis

John Wernert, M.D.

Disclosure: All planners and speakers associated with this session disclose that they have no relevant relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Watch session here: https://youtu.be/q14o6KCUCAI

  • Be able to describe benefits versus risks of use of medical cannabis
  • Be able to properly identify patient and product selection.

Current Drug Trends as Seen on the Streets

Detective Tate Mason

Disclosure: All planners and speakers associated with this session disclose that they have no relevant relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Watch session here: https://youtu.be/zOOosmRERXo

  • Describe new and emerging street drugs that physicians may encounter in practice.

Aging, Addiction and Polypharmacy: Managing Medication Complexity in Older Adults with Substance Use Disorders

Chris Stewart, M.D.

Disclosure: All planners and speakers associated with this session disclose that they have no relevant relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Watch session here: https://youtu.be/cPkWPMTIDDk

  • Describe the epidemiology of polypharmacy and substance use disorders among older adults and their impact on morbidity and mortality.
  • Recognize common medication combinations that increase the risk of falls, cognitive impairment, respiratory depression, overdose, and hospitalization.
  • Apply evidence-based prescribing, deprescribing, and harm reduction strategies when treating older adults with substance use disorders.
  • Integrate current evidence regarding medications for opioid use disorder into the care of medically complex older adults.
  • Develop individualized treatment plans that reduce medication burden while maintaining safe and effective treatment of pain, psychiatric illness, and substance use disorders.

The Nature of SDU Treatment

Kelly Clark, M.D., MBA

Disclosure:  All planners associated with this session disclose that they have no relevant relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Watch session here: https://youtu.be/kw98AcVwn2E

Kelly Clark, M.D., MBA-Speaker,  discloses  the following relevant financial relationships with an ACCME ineligible companies defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:   
Sophrosyne, Consultant                             
Habit Halo, Consultant

  • Be able to better identify patient for SUD Treatment
  • Modify my communication with patients and caregivers regarding treatment for patients
  • Increase my engagement with SUD treatment providers.